|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Social Anxiety Disorder | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Anxiety Disorders | |||||
| Disease | |||||
| Phobic Disorders | |||||
| 3 | More general conditions related to this trial | ||||
| Mental Disorders | |||||
| Pathologic Processes | |||||
| 4 | Interventions listed in this trial | ||||
| GSK561679 | |||||
| GW876008 | |||||
| alprazolam | |||||
| 5 | More general drug interventions related to this trial | ||||
| Anti-Anxiety Agents | |||||
| Central Nervous System Agents | |||||
| Central Nervous System Depressants | |||||
| GABA Agents | |||||
| GABA Modulators | |||||
| Hypnotics and Sedatives | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Neurotransmitter Agents | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Psychotropic Drugs | |||||
| Therapeutic Uses | |||||
| Tranquilizing Agents | |||||
| 6 | Sponsors listed in this trial | ||||
| GlaxoSmithKline | |||||